动物造模,尿酸排泄不良型高尿酸血症动物模型 z-bio 2022-11-10 337

　　Objective: To explore a reliable method to establish a rat model of dysuricemia, and lay a foundation for the study of the pathogenesis of dysuricemia and the optimization of the treatment plan.

　　Methods: Potassium oxyzinate (300 mg/kg), pyrazinamide (300 mg/kg) and ethambutol (250 mg/kg) were used to establish the model. After continuous administration for 1 week, 3 weeks and 5 weeks, the levels of uric acid in blood, urine and stool of rats were detected, and the functions of liver and kidney were also detected, and histological pathological sections were observed.

　　Results: The serum uric acid of the rats in the combined model group of potassium oxyzinate and ethambutol increased first and then decreased, while the serum uric acid and urine uric acid in the combined model group of potassium oxyzinate and pyrazinamide increased steadily during continuous administration. Both methods had no obvious damage to liver and kidney.

　　Conclusion: The combination of potassium oxyzinate and pyrazinamide can effectively establish a rat model of dysuricemia with good stability, and its pathogenesis is more consistent with the clinical course of dysuricemia.